when Boone Pickens can't get financing.Story on the collapse of his wind farm dreams here.
You've heard that Sarah Palin resigned. Have you heard this?
The 1990 Jeep Grand Wagoneer is available here on eBay Motors for bidding or an $11,000 BuyItNow price tag. Consider it the yin to my Prius yang.
Even Puma got in on the action with its Cali Woody (no longer available and originally available only at its Santa Monica store, natch).
It is 4:45 a.m. and I have been up for over an hour listening to the carnage.





I also found out through My Grey Gardens that Grey Gardens the Musical will be in Philadelphia May 22 through June 28. Guess who will be going?
Gwyneth Paltrow Nourishes Her Inner Aspect."Dear child laborers," it would begin. "Seek your happiness." Blah blah blah, her assistant would know how to end it. She was always much better at writing letters, and aspirational websites, than Gwyneth.
Gwyenth slipped into her polar bear fur lined slippers and headed to the 4,000 square foot master bathroom to prepare her morning toilette. She rinsed her mouth with calf's milk and brushed her teeth with fresh mint leaves. She soaked for an hour and a half in the Olympic size Jacuzzi before calling out for the breakfast servant to bring her her egg white omelet with truffle shavings and gold leaf. What many people didn't realize was that eating gold was actually good for you. Although there were no particular nutritional benefits, it just made you feel good to be able to eat gold. She ate gold at every meal. That would be one of her next newsletters. "Everyone Should Just Eat Gold."
For the entire hilarious article, click here.
Even though I made amends with Gwyneth in this post, I really cannot believe I didn't write this.
Thanks to my little buttercup, Raina of If the Lampshade Fits, for this amusing lampoonery. And here's to Gabe, for writing it.

Category: Developmental Therapeutics: Molecular Therapeutics
Meeting: 2009 ASCO Annual Meeting
Citation: J Clin Oncol 27:15s, 2009 (suppl; abstr 3520)Abstract No: 3520
Author(s):
Background: ENMD-2076, a novel, orally-active antimitotic and antiangiogenic molecule inhibits Aurora A as well as tyrosine kinases that drive tumor vascularization, including VEGFR2 (KDR), PDGFR and the FGF receptors. This Phase 1 study was designed to evaluate the safety, pharmacokinetics (PK) and preliminary efficacy of ENMD-2076 administered once daily to patients (pts) with advanced cancer. Methods: The dose escalation scheme utilizes 3 (or 4) + 3 (or 2) design. Pts receive ENMD-2076 once daily in 28-day cycles (followed by 7-14 days of rest between cycles 1 and cycle 2 only). Results: 14 pts have been enrolled in 3 dose cohorts (range 60 to 120 mg/m2/d). Median age/performance status is 62/1. The total number of treatment cycles to date is 45, with a median of 3 cycles (range <1 n="14)">2/d. Following drug interruption, the pt restarted at 30 mg/m2/d and continued for 4 additional cycles before being removed for progressive disease. Noncompartmental PK analysis of the first two dose levels shows that the plasma concentration of ENMD-981693 (the active free base of ENMD-2076) is dose- linear, as reflected in AUC and Cmax. The estimated terminal half-life (t1/2) is unaltered regardless of dose; however, t1/2 is approximately 50% greater at steady state than following single dose administration. Four ovarian cancer and 2 colon cancer pts have achieved decreases ranging from 11-61% in either CA125 or CEA, respectively (4 are associated with stable disease at Cycle 2 by modified RECIST criteria). Serum KDR concentrations assayed by ELISA decreased from baseline in all patients on treatment from a mean of 9153 pg/mL (SEM 464.2) at D1 to 6987 pg/mL (SEM 460.0) at D28 (p <0.05).>Conclusions: ENMD-2076 is a small molecule kinase inhibitor with acceptable toxicity and preliminary evidence of antitumor activity in pts with ovarian and colorectal cancers.
(The final bold is mine.)
If this is true, this could be HUGE!!!!!!!!! This is on actual patients, people!!
I love you, Entremed researchers and docs involved with this clinical trial. With all my heart.
Tune in to the annual ASCO meeting on May 30, 2009 for the actual presentation of trial results. Or my blog.